Age alone should not determine whether a patient gets a device
At the EuroPCR 2026 cardiology congress, researchers presented findings from the CHAMPION-AF trial suggesting that a small implantable device designed to seal off a clot-forming pouch in the heart performs as well as lifelong blood thinners for stroke prevention in atrial fibrillation patients — regardless of whether they are younger or older than 75. The finding quietly dismantles a long-standing assumption that age alone should guide treatment decisions for one of the world's most common heart conditions. What emerged most clearly was not a winner between device and drug, but a reminder that medicine's deepest work happens not in data tables, but in the unhurried conversation between a clinician and the particular human before them.
- For decades, older atrial fibrillation patients have been steered toward or away from certain therapies based on age alone — a practice this trial now directly challenges.
- The CHAMPION-AF trial enrolled 3,000 patients suitable for standard anticoagulation and split them evenly between a left atrial appendage closure device and a direct oral anticoagulant, tracking outcomes over three years.
- The device matched blood thinners for stroke prevention in both age groups, but delivered a striking advantage on bleeding — reducing major bleeding events by roughly a third across the board.
- A nuance in the data tempers the headline: when only patients who received their assigned treatment as planned were analyzed, the small numerical gap in ischemic stroke rates between device and drug effectively vanished.
- Researchers and clinicians are now being urged to move away from age-based defaults and toward individualized, shared decision-making that weighs bleeding history, kidney function, and patient preference.
Cardiologists at EuroPCR 2026 heard results that could quietly reshape how atrial fibrillation — a condition where the heart's upper chambers quiver rather than beat steadily — is managed across a lifetime. The disorder carries a serious stroke risk: blood pools, clots form, and those clots can travel to the brain. For decades, the answer has been anticoagulant medication, taken for life. But blood thinners carry their own danger, raising the risk of serious bleeding elsewhere in the body.
The left atrial appendage closure device offers an alternative. A small mesh implant placed by catheter, it seals off the heart pouch where most clots originate. Previously reserved for patients who couldn't tolerate anticoagulants, the CHAMPION-AF trial asked a bolder question: could it work just as well for everyone else, too?
Researchers enrolled 3,000 patients who were genuine candidates for standard anticoagulation, splitting them evenly between the device and a direct oral anticoagulant. A subanalysis presented by Jens Erik Nielsen-Kudsk divided the results by age — 1,915 patients under 75, and 1,085 aged 75 and older. The finding was striking in its consistency: age made no meaningful difference. The device matched anticoagulants for stroke prevention in both groups, and the statistical test for whether age changed the answer came back negative.
On bleeding, the device pulled ahead decisively — younger patients saw 36 percent fewer major bleeding events, older patients 32 percent fewer, both statistically significant. A caveat appeared in the fine print: among patients who received their assigned treatment exactly as planned, the slight numerical disadvantage for the device in ischemic stroke rates disappeared, suggesting that real-world procedural delays or complications may have shaped the overall numbers.
The message from EuroPCR was measured but clear. A patient's birthday should not determine their treatment. The real work, researchers emphasized, lies in the clinic — in conversations that weigh bleeding history, kidney function, the practicalities of daily medication, and personal preference. The choice between device and drug belongs to doctor and patient together, not to a number on a birth certificate.
Cardiologists gathered at EuroPCR 2026 to hear results that could reshape how doctors treat one of the heart's most common rhythm disorders. Among three major trials unveiled for the first time, one stood out for what it didn't find: no meaningful difference based on age.
Atrial fibrillation—a condition where the heart's upper chambers quiver instead of beating steadily—carries a serious risk. Blood pools and clots form, and those clots can travel to the brain and cause stroke. For decades, the standard answer has been anticoagulant medication: blood thinners taken by mouth, usually for life. But these drugs come with their own danger. They prevent clots, yes, but they also increase the risk of bleeding elsewhere in the body—sometimes catastrophically.
Enter the left atrial appendage closure device. It's a small mesh implant, placed through a catheter, that seals off a pouch in the heart where clots tend to form. For patients who couldn't tolerate anticoagulants—those with histories of bleeding, or allergies, or simply intolerance to the drugs—LAAC offered an alternative. But what about everyone else? What about patients healthy enough to take anticoagulants safely? Could the device work just as well, and perhaps with fewer bleeding complications?
The CHAMPION-AF trial set out to answer that question. Researchers enrolled 3,000 atrial fibrillation patients who were actually suitable candidates for anticoagulation—the traditional first-line therapy. Half received a LAAC device. Half received a direct oral anticoagulant, or DOAC. Then they watched. Over three years, they tracked deaths from heart causes, strokes, blood clots traveling elsewhere in the body, and bleeding events.
Jens Erik Nielsen-Kudsk presented a subanalysis that broke the results down by age. This mattered because older patients are often treated differently than younger ones, sometimes excluded from certain therapies simply because of their years. The study included 1,915 patients under 75 and 1,085 patients 75 and older. What the researchers found was striking in its consistency: age made no real difference.
For the main safety question—preventing stroke and clots—LAAC performed just as well as anticoagulants in both age groups. In younger patients, the hazard ratio was 1.07, meaning LAAC had a 7 percent higher numerical risk, but the confidence interval was wide enough that this could easily be chance. In older patients, the ratio was 1.34, again not statistically significant. The interaction test—the statistical way of asking whether age changed the answer—showed no meaningful difference between groups.
But on bleeding, LAAC pulled ahead decisively. Younger patients on LAAC had 36 percent fewer major bleeding events than those on anticoagulants. Older patients saw a 32 percent reduction. Both differences were statistically significant. Disabling strokes—the kind that leave lasting damage—were rare and similar across all groups.
One caveat emerged in the fine print. When researchers looked only at patients who actually received their assigned treatment as planned, the difference in ischemic stroke rates between LAAC and anticoagulants disappeared. This suggests that the device's slight numerical disadvantage in the overall analysis may have reflected the reality of clinical practice: some patients assigned to LAAC never got it, or got it late, or had complications that delayed the procedure.
The message from EuroPCR was clear but measured. Age alone should not determine whether a patient gets a LAAC device. A 78-year-old with atrial fibrillation and a history of bleeding is not automatically worse off choosing the device than a 65-year-old. But the researchers also sounded a note of caution: subgroup analyses have limits. They're less powerful than the main trial results. The real work happens in the clinic, in conversation between doctor and patient, weighing individual circumstances—not age, but bleeding history, kidney function, ability to take pills reliably, personal preference. The choice between device and drug should be made together, not dictated by a birthday.
Citas Notables
The efficacy and safety of LAAC vs. DOAC are not affected by age— CHAMPION-AF trial findings
The choice between LAAC and DOAC should be made on an individualised basis in a shared decision-making process with patients— EuroPCR Course Directors conclusions
La Conversación del Hearth Otra perspectiva de la historia
Why does age matter so much in how doctors treat atrial fibrillation right now?
Because older patients bleed more easily, and anticoagulants thin the blood. Doctors have been cautious, sometimes avoiding the drugs altogether in elderly patients, even when they might help. So there's been an assumption that older hearts need different solutions.
And this study found that assumption was wrong?
Not entirely wrong—older patients do have more bleeding risk on anticoagulants. But the LAAC device reduced that risk equally well in both age groups. So the device wasn't less safe or less effective in older people. That's the surprise.
What about the stroke prevention itself? Did the device actually prevent strokes as well as the blood thinners?
Yes. Over three years, the rates of stroke and death were essentially the same. The device didn't protect better, but it didn't protect worse either. And it did so with significantly less bleeding.
So why wouldn't every atrial fibrillation patient just get the device?
Because it requires a procedure. There's a small risk during implantation, recovery time, and ongoing monitoring. Some patients do fine on anticoagulants and prefer to avoid surgery. The point is that age shouldn't be the deciding factor—individual circumstances should be.
What happens now? Do cardiologists change how they practice?
Gradually, probably. This gives them permission to offer LAAC to older patients without guilt, and to have honest conversations about trade-offs instead of defaulting to age-based rules. But it's not a mandate. Medicine doesn't work that way.